<?xml version="1.0" encoding="UTF-8"?>
<p id="Par24">In general, mild COVID-19 illness in people with type 2 diabetes on oral agents may be allowed to keep their usual treatment, provided that the patient stays under well control, but treatment modification must be indicated immediately upon clinical judgement, if development of severe COVID-19-related symptoms appear, especially high fever and potential dehydration. Oral agents, particularly metformin and sodium glucose cotransporter-2 inhibitors need to be stopped also, if serious illness condition develops [
 <xref ref-type="bibr" rid="CR26">26</xref>]. Insulin is the preferred agent to control hyperglycemia in hospitalized patients, as it the most efficacious for any intercurrent situation, including infections [
 <xref ref-type="bibr" rid="CR4">4</xref>]. Although sodium glucose cotransporter-2 inhibitors may predispose to ketoacidosis, a controversial clinical trial with dapaglifozin has been approved in COVID-19 patients with moderate illness including respiratory failure, the DARE-19 study (NCT04350593), aiming to evaluate the reduction of disease progression and death.
</p>
